Psoriatic arthritis (PsA) is a disease where the immune system attacks the joints, causing pain and swelling. This study is testing sonelokimab to see if it's safe and effective for adults with PsA who didn't improve with previous anti-tumor necrosis factor (TNFα) treatments. The study compares sonelokimab with a placebo (a harmless pill that doesn't contain medicine) and another drug called risankizumab to see which works better.
Participants need to be at least 18 years old and must have had joint pain and swelling for at least 6 months. They should have tried and not responded well to 1 or 2 previous TNFα treatments.
- Duration: The study is a Phase 3 trial, meaning it's advanced and thorough.
- Visits Required: Participants will be part of a multicenter study, requiring multiple visits.
- Eligibility: Patients with other chronic inflammatory diseases or previous exposure to sonelokimab can't join.
How understandable was the trial content above?
Hard to understand
Easy to understand